What is CRP and what does it have to do with your health?

What is CRP?

CRP stands for C-reactive protein.  This protein is produced by the liver in response to elements released from certain white blood cells known as macrophages; as well as elements released from fat cells (adipocytes.)  CRP levels rise in the presence of inflammation and take on a role to bind with chemical compounds that are released on the surface of a dying or dead cell.  This process is part of an immune system response to enhance the ability of antibodies and bacteria/pathogen eating cells (phagocytic cells) to eliminate damaged cells from the body.  Certain chronic inflammatory conditions cause the release of IL-6 (interleukin-6) that trigger the release of CRP.  IL-6 is a type of immune protein in the family of cytokines that can act as both an anti-inflammatory and a pro-inflammatory.

As discussed in previous blog posts, inflammation is a normal body process necessary for our body’s response to fight infection and injury.  It is a natural part of our immune system’s ability to send white blood cells and other chemical compounds to a trouble area of the body in an effort to help it heal.  However, in the presence of chronic conditions such as Arthritis, Colitis, Bursitis, Tendonitis, Gout, Heart Disease, Asthma, Diabetes, and more – the constant “fire” of inflammation can be disastrous, even deadly.
Continue reading “What is CRP and what does it have to do with your health?”

Please follow and like us:

New evidence of increased risk of death with Febuxostat (Uloric)

According to the latest CARES trial, the Gout drug Febuxostat (Uloric) failed up against Allopurinol when it came down to a combined rate of fatal and nonfatal adverse events for those that suffer with both Gout and Cardiovascular disease.  In fact, there was a significant increased risk of death for those that took this drug for Gout while also suffering from heart disease.

The trial was mandated by the FDA and consisted of 6,190 patients, 84% of which were men.  Cardiovascular risk is naturally increased in patients with Gout.  The study was attempting to look at any difference in outcome for these patients taking Febuxostat, a nonpurine xanthine oxidase inhibitor, or those taking Allopurinol, a purine base analogue xanthine oxidase inhibitor.  The patients were followed for a median of 32 months, and a maximum of 85 months.  Without diving into all of the ratio statistics, the all-cause and cardiovascular mortality rate was higher in the Febuxostat group, 34% and 22% higher respectively. Continue reading “New evidence of increased risk of death with Febuxostat (Uloric)”

Please follow and like us: